National Lab Briefs

Argonne Reactor Program Turns To The East Faced with dwindling U.S. interest in nuclear power research, Argonne National Lab has turned to Japan to save its reactor research program. In July the lab reached an agreement with the Japanese electric industry that will see $20 million over five years poured into a lab program on “pyrometallurgical” fuel reprocessing. The technique separates radioactive elements from used fuel for recasting into new fuel, thereby allowing the reactor to

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Faced with dwindling U.S. interest in nuclear power research, Argonne National Lab has turned to Japan to save its reactor research program. In July the lab reached an agreement with the Japanese electric industry that will see $20 million over five years poured into a lab program on “pyrometallurgical” fuel reprocessing. The technique separates radioactive elements from used fuel for recasting into new fuel, thereby allowing the reactor to bum its own waste. But the process is at least a decade away from commercial application, says Argonne project manager Yoon Chang, and the listless U.S. nuclear industry is “not looking at long-term energy policy.” The Japanese involvement comes as Congress threatens to cut funding for Argonne’s entire Integral Fast Reactor program to as little as a third of the $30 million the Department of Energy requested in its 1990 budget.

“Without the Japanese [investment] we would have had problems supporting ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies